Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Accumulated Expenses: 2023-2024

Historic Accumulated Expenses for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $8.2 million.

  • Monte Rosa Therapeutics' Accumulated Expenses rose 126.76% to $8.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.0 million, marking a year-over-year increase of 126.76%. This contributed to the annual value of $8.2 million for FY2024, which is 8.26% up from last year.
  • Monte Rosa Therapeutics' Accumulated Expenses amounted to $8.2 million in FY2024, which was up 8.26% from $7.6 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Accumulated Expenses high stood at $8.2 million for FY2024, and its period low was $7.6 million during FY2023.
  • Moreover, its 2-year median value for Accumulated Expenses was $7.9 million (2023), whereas its average is $7.9 million.
  • Data for Monte Rosa Therapeutics' Accumulated Expenses shows a peak YoY climbed of 8.26% (in 2024) over the last 5 years.
  • Over the past 2 years, Monte Rosa Therapeutics' Accumulated Expenses (Yearly) stood at $7.6 million in 2023, then grew by 8.26% to $8.2 million in 2024.